Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutikizumab + ABBV-701
- Development stage
- Preclinical
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Lutikizumab + ABBV-701 is an investigational combination therapy being developed by AbbVie for the treatment of moderate to severe hidradenitis suppurativa (HS). The combination consists of lutikizumab (ABT-981), a dual-variable-domain immunoglobulin (DVD-Ig) that neutralizes both interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), and ABBV-701 (FG-M701), a fully human monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). By simultaneously targeting the IL-1α/β and TL1A pathways, the combination is designed to address multiple complementary inflammatory cascades to improve clinical outcomes in patients with HS. AbbVie plans to evaluate this combination as part of an HS platform study program.
- Other names
- ABT-981 + ABBV-701ABT-981 + FG-M701lutikizumab + FG-M701
02
Targets
Beyond the preview
Go deeper on lutikizumab + ABBV-701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutikizumab + ABBV-701.